---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060828"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:52:31.836858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports positive Phase 2 Cohort 5 data for infigratinib in achondroplasia; mean AHV increase +3.03 cm/yr

## Summary
- Mean change from baseline in annualized height velocity (AHV) at six months: +3.03 cm/yr (p=0.0022) in Cohort 5 (0.25 mg/kg daily).
- 80% of 10 children with six-month visits were responders (≥25% increase in AHV); mean change among responders +3.81 cm/yr.
- No treatment-related adverse events in Cohort 5; no SAEs or discontinuations in any cohort.
- BridgeBio has started enrolling children in a Phase 3 trial and plans to initiate development for hypochondroplasia.
- Median absolute AHV reached 7.6 cm/yr, beyond the 99th percentile for achondroplasia.

## SEC filing metadata
- accession: 0001193125-23-060828
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/0001193125-23-060828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/d467337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060828
- JSON: https://secwatch.observer/filing/0001193125-23-060828.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.